Quick Answer
Protagonist Therapeutics, Inc reported R&D Expense of $159.29 million for fiscal year 2025.
Protagonist Therapeutics, Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $159.29M | +15.3% |
| 2024 | $138.13M | +15.0% |
| 2023 | $120.16M | -4.8% |
| 2022 | $126.22M | +0.2% |
| 2021 | $126.01M | +69.1% |
| 2020 | $74.51M | +14.6% |
| 2019 | $65.00M | +9.3% |
| 2018 | $59.50M | +28.8% |
| 2017 | $46.18M | +79.7% |
| 2016 | $25.70M | +117.3% |
| 2015 | $11.83M | +58.6% |
| 2014 | $7.46M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.00M | +11.2% | +8.0% |
| June 30, 2025 | $37.04M | +10.5% | +3.2% |
| March 31, 2025 | $35.89M | +6.4% | -0.2% |
| September 30, 2024 | $35.97M | +17.3% | +7.3% |
| June 30, 2024 | $33.52M | +1.0% | -0.6% |
| March 31, 2024 | $33.73M | +23.0% | +10.0% |
| September 30, 2023 | $30.66M | +20.7% | -7.6% |
| June 30, 2023 | $33.18M | -4.1% | +21.0% |
- Protagonist Therapeutics, Inc showed an increase of +15.3% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Protagonist Therapeutics, Inc’s r&d expense has grown by 2035.5% (from $7.46 million to $159.29 million).
- The most recent figure is from Protagonist Therapeutics, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: